FDA Expands Use of RSV Vaccine to Include More Adults

Source link :

The FDA expanded the approval of GSK’s respiratory syncytial virus (RSV) vaccine (Arexvy) to include adults ages 50 to 59 at risk of RSV-related lower respiratory tract disease (LRTD) due to underlying conditions, the company announced on Friday. Previously the adjuvanted RSV prefusion F protein-based vaccine had been approved only for adults 60 and older; […]

Author : News Health

Publish date : 2024-06-10 15:41:39

Copyright for syndicated content belongs to the linked Source.